NewzPresident Trump announced on Monday in the Oval Office that his administration has reached agreements with nine pharmaceutical and biotechnology companies to lower prescription drug costs for Americans. The deals specifically target Medicaid drug pricing and aim to reduce the costs of treatments for conditions including Parkinson's disease, macular degeneration, glaucoma, and liver disease.
During the announcement, the President stated that the drugs involved in these agreements will be offered at the lowest prices available globally. The initiative involves midsize firms and represents a formal effort by the administration to address rising pharmaceutical expenditures through direct negotiation with manufacturers.
In-depth summary · AI, neutral